Neurobiology of Alzheimer's Disease

ISBN-13: 9780198566618 / Angielski / Twarda / 2007 / 536 str.

David Dawbarn; Shelley J. Allen

Opis

Alzheimer's disease is the most common form of dementia in the elderly; 450,000 people in the UK and 4.5 million people in the USA suffer with this disease. This 3rd edition of Neurobiology of Alzheimer's Disease gives a comprehensive and readable introduction to the disease, from molecular pathology to clinical practice. The book is intended for readers new to the field, and it also covers an extensive range of themes for those with in-depth knowledge of Alzheimer's disease. It will therefore act either as an introduction to the whole field of neurodegeneration or it will help experienced researchers to access the latest research in specialist topics. Each chapter is written by eminent scientists leading their fields in neuropathology, clinical practice and molecular neurobiology; appendices detail disease-associate proteins, their sequences, familial mutations and known structures.

Recenzje

essential reading...accessible and useful to...students, researchers, clinicians and pharmacists

O autorze

David Dawbarn obtained his PhD from the University of Bristol and then initiated his work on Alzheimer's disease (AD) at the Medical Research laboratories in Cambridge as a Research Fellow. He returned to Bristol to take up a lectureship investigating the molecular pathology of Alzheimer's disease and developing new therapies. His interests are in nerve growth factor (NGF) and Alzheimer's disease; his early work described the distribution of NGF receptors in the brain, showing their specific localisation on cholinergic neurons. The identity of the NGF binding site on its receptor was then determined. The domain was made as a recombinant protein, crystallised and its structure solved. The coordinates of the structure are currently being used for the development of small molecule therapeutics for the treatment of Alzheimer's disease. Shelley Allen obtained her PhD at the Institute of Neurology in London, and her work in the early eighties with David Bowen started her interest in the cholinergic changes in Alzheimer brain. Later at Bristol she investigated the characterisation of human cholinergic basal nucleus in terms of the nerve growth factor (NGF) receptor. She has continued this work on the neurotrophins and the possibility of a neurotrophin related therapeutic for Alzheimer's disease. In addition she is especially interested in the influence of cholinergic activity on Alzheimer-associated pathogenic processes. Her work recently has also shown variously the synaptic loss associated with the E4 allele of apolipoprotein E in normal individuals and the increase in BACE activity in sporadic Alzheimer's disease.